Aethlon Medical (Nasdaq: AEMD) did not provide a revenue figure for fiscal Q1 2027; it reported a basic and diluted net loss of $4.02 per share, compared with $42.42 a year earlier, while net loss narrowed to $1.55 million from $1.76 million. Lower professional, administrative and preclinical research costs reduced operating expenses, while the Hemopurifier program advanced into the final dosing cohort of its Australian Phase 1 oncology study.

Core financial results

With no revenue disclosed, the quarter’s financial improvement came primarily from lower spending. Operating expenses declined 11.9% to $1.58 million, led by professional fees falling to $333,569 from $476,032 and general and administrative expenses decreasing to $662,450 from $735,358. Payroll and related expenses were nearly unchanged at $583,183.

Operating loss and net loss both narrowed by approximately 12%. The improvement in loss per share was much larger, but this reflected a substantial increase in the weighted-average share count rather than a comparable change in the underlying loss.

Net interest income was $31,290, compared with $30,532 in the prior-year quarter, and therefore had little effect on the year-over-year change in net loss.

Hemopurifier clinical program advances to the final cohort

Aethlon treated the first participant in the third and final dosing cohort of its Phase 1 oncology study in Australia. Early observations from the first two cohorts included consistent decreases in tumor-derived extracellular vesicles and microRNAs associated with cancer progression, along with changes in immune function associated with a potential response to immunotherapy.

These observations remain preliminary and will be evaluated after the study is completed. The company explicitly cautioned that the Hemopurifier is investigational, its safety and effectiveness have not been established, and the early findings should not be interpreted as evidence of clinical benefit.

A Long COVID manuscript was also accepted for publication in the International Journal of Molecular Sciences. The research found that extracellular vesicles isolated from the plasma of people with Long COVID bind to the proprietary GNA affinity resin used in the Hemopurifier. This supports further study of the platform in post-viral conditions but does not establish a therapeutic outcome.

Cash position and financing

Cash and cash equivalents were $4.93 million on June 30, 2026, down approximately $92,879, or 1.8%, from March 31. Current liabilities declined to $1.04 million from $1.45 million over the same period. The release did not include a cash flow statement, so operating cash usage cannot be assessed directly from the reported cash balance.

After quarter-end, Aethlon raised approximately $4.0 million in gross proceeds through a public offering of common stock. Based on current plans and including its available resources, management believes the company can fund operations for at least the next 12 months. The amount represents gross proceeds, and the release did not provide net proceeds after offering costs.

The larger share count magnified the EPS improvement

The reduction in loss per share was much greater than the underlying improvement in net loss. Net loss narrowed by about 12.1%, while the weighted-average share count increased more than ninefold to 384,705. Investors therefore should not interpret the move from a $42.42 loss per share to a $4.02 loss per share as a similar-sized improvement in operating performance.

Quarter-end common shares outstanding also increased to 477,402 from 314,100 at March 31, a rise of approximately 52%. The subsequent public offering provided additional liquidity but also involved further common-stock issuance; the number of shares sold in that offering was not disclosed in the release.

Recent insider transactions

The available two-year insider dataset contains eight specific transactions, all of which were direct stock awards to directors rather than open-market purchases or sales. Each of the four directors received awards in April 2025 and April 2026.

Because these transactions were compensation-related grants, they should not be treated as evidence of discretionary insider buying.

Risks investors need to watch

• Clinical evidence remains preliminary: The biomarker observations came from an early feasibility study and do not demonstrate that the Hemopurifier is safe, effective or clinically beneficial.
• Trial execution could affect development timelines: Enrollment, site approvals in Australia, regulatory requirements and the ability to manufacture enough Hemopurifier devices could influence study completion.
• Additional financing may create dilution: Aethlon continues to generate losses and did not disclose revenue. Its 12-month liquidity assessment depends on current operating plans, while common-share issuance has already increased the share count.
• Listing and regulatory risks remain: The company identified maintaining its Nasdaq listing and navigating potential changes in regulatory requirements as continuing uncertainties.

Summary

Aethlon’s fiscal Q1 2027 loss narrowed as professional and administrative spending declined, but the much larger improvement in loss per share mainly reflected a sharply higher share count. The post-quarter offering strengthened near-term liquidity, while the central operating milestone was advancement of the Australian oncology study into its final dosing cohort. The next meaningful developments will be fuller clinical results, progress in enrollment and site execution, and whether the company can manage its cash needs without substantial additional dilution.

Find out more